Full-Time

Executive Director

Adaptive Immune Tolerance, Immune Therapeutics

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Current presence or willing to relocate to Cambridge vicinity.

Category
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • A Ph.D. in immunology or related discipline with 15+ years of experience in an academic and industry setting.
  • Creative and expert knowledge of adaptive (T and B cell) immunology as demonstrated by high-impact publications and international recognition in academia and/or industry.
  • Proven experience in advancing therapeutic candidate from discovery through to clinical development, including leading programs that have successfully reached clinical trials in patients.
  • Demonstrated ability to conceive and evolve state-of-the-art cellular and molecular assays and in vivo inflammatory and autoimmune model systems.
  • Exceptional collaboration skills in a cross-functional matrixed environment.
  • Proven track record to manage and motivate a team of scientists and associates in a fast paced dynamic environment.
  • Strong verbal and communication skills, and ability to maintain organized and detailed research records.
  • Ability to lead multiple projects in a fast-paced environment.
  • Experience or knowledge with pharmacology, biomarker and translational medicine in developing nucleic acid therapeutics is also preferred.
  • Highly effective leadership, including training and developing individual talent and building high-performing teams.
  • Ability to relentlessly prioritize and align efforts with high impact opportunities.
  • Current presence or willing to relocate to Cambridge vicinity.
Responsibilities
  • Apply deep expertise in immunology and contribute to the science strategy, applying deep domain expertise to conceptualize approaches to enable expanded portfolio applications for our mRNA platform technology.
  • Champion a culture that values respectful and candid scientific debate, drives toward decision-making experiments, obsesses over learning from unexpected results, and celebrates both Go and No-Go decisions.
  • Provide direct scientific leadership to cross-functional program leads within Immune Therapeutics.
  • Define and lead the organization to execute against scientific deliverables with a sense of urgency.
  • Manage functional budgets, optimize resource allocation, and spearhead technological investments, including automation and digital transformation initiatives.
  • Establish strong working relationships with key stakeholders and collaborators in the R&ED ecosystem.
  • Deliver high-quality scientific presentations internally and externally to a variety of audiences, including leadership teams, governance committees, and scientific conferences.
  • Conceptualize and contribute to peer-reviewed research articles and patent applications.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

15%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?